3728 Jinke Rd, Bldg 1, West Wing, Shanghai, China info@tyligand.com

Research Platform

DATIA® (Dual Action Tumor Immune Agonist)

Tyligand Bioscience's DATIA® (Dual Action Tumor Immune Agonist) platform is based on the concept of "creative connection", aiming to address the durability issue of previous immune agonists in cancer therapy. The DATIA® series of compounds have unique pharmacokinetic properties modulated by enzymes rich in the tumor microenvironment, achieving a balanced activation of immune cells and immunogenic killing of tumor cells.


Chemical Manufacturing and Control (CMC) Capabilities

Tyligand is a leader in complex small molecule API and formulation process design, pilot-scale production, and high-quality material delivery. Our world-class capabilities enable us to develop robust manufacturing processes and accelerate the development of drug candidates.